Plumbing the Depths of a Pipeline

Mar 01, 2001

Premium

As the line between pharma and biotech gets blurrier, Bayer has agreed to outsource some of its preclinical testing to CuraGen. In the smaller part of a two-pronged, billion-dollar-plus deal, Bayer committed $39 million over five years for CuraGen’s pharmacogenomic and toxicogenomic technologies and invested $85 million in its stock.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

What You Might Learn

The UK's Human Fertility and Embryology Authority calls for consumer genetic testing companies to warn customers that testing could uncover family secrets, according to the Guardian.

From Whales to Urchins to Algae

The New York Times reports that United Nations delegates have been discussing how to govern the genetic resources of the deep sea.

In the Skin

Researchers have transplanted edited cells into mice that appear to combat cocaine addiction, New Scientist reports.

This Week in PNAS

In PNAS this week: analysis of proteolytic enzymes secreted by circulating tumor cells, phylogenetic study of Fv1 evolution, and more.

Main menu